Sutro Biopharma: Transition to STRO-004–Driven Clinical Execution Warrants Hold as Long-Term Upside Meets Near-Term Uncertainty
at www.tipranks.com (Mon, 22-Dec 6:25 AM)
Sutro Biopharma Advances STRO-004 with First Patients Dosed in Pioneering Phase 1 Study
Market Chameleon (Thu, 4-Dec 10:03 AM)
